跳至主要内容
临床试验/jRCT2080220715
jRCT2080220715未知3 期

A Comparison of Symbicort SMART (160/4.5mcg) and Symbicort Turbuhaler 160/4.5mcg, Plus Terbutaline Turbuhaler 0.4mg as Needed, for Treatment of Asthma - a 12-Month, Randomized, Double-Blind, Parallel Group, Active-Controlled, Multinational Phase 3 Study in Asthmatic Patients From 16 Years

AstraZeneca0 个研究点开始时间: 待定
适应症

试验速览

阶段
3 期
发起方
AstraZeneca

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
干预模型
Double Blind, Efficacy Study, Parallel Assignment, Randomized, Treatment

入排标准

年龄范围
16age old over 至 No limit(—)
性别
All

入选标准

  • Diagnosis of asthma according to GINA 2007 with a documented history of at least 6 months duration
  • Turbuhaler-Prescribed use of inhaled GCS (any brand) for at least 12 weeksAges
  • Reversible airway obstruction, defined as an increase in 12% of FEV1 or more relative to baseline for all patients 15-30 minutes after inhalation of in total 2 x 0.4 mg terbutaline

排除标准

  • Respiratory infection affecting the asthma, as judged by the investigator within 4 weeks
  • Intake of oral, rectal or parenteral GCS within 4 weeks and/or depot parenteral GCS within 12 weeks

研究者

发起方
AstraZeneca

相似试验